Bentley Pharmaceuticals to Release Fourth-Quarter 2007 Financial Results on March 13, 2008

Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, today announced that management will host a conference call to discuss fourth-quarter and year-end 2007 financial results on Thursday, March 13, 2008, at 10:00 a.m. (ET). On the call, the Company will also provide an update on the ongoing process of separating its drug delivery business from its generic pharmaceuticals business. Bentley will release its results for the three months and full year ended December 31, 2007, before the market opens on that day. To participate on the live call, please dial (888) 332-7254 or (973) 582-2856 for international callers. The access code for the call is 33823748. The conference call will also be webcast live and may be accessed via Bentley’s website, www.bentleypharm.com. A telephone replay will be available for 30 days by dialing (800) 642-1687 or (706) 645-9291 for international callers. Please reference reservation number 33823748. A replay of the conference call also will be available on Bentley’s website for 30 days. Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and generic pharmaceutical products. Bentley’s proprietary drug delivery technologies enhance the absorption of pharmaceutical compounds across various membranes. Bentley plans to spin off its drug delivery business as an independent, publicly traded company. Its newly formed subsidiary, CPEX Pharmaceuticals, Inc., has filed an initial registration statement on Form 10 with the Securities and Exchange Commission (SEC) in furtherance of this plan. Completion of the proposed spin-off is subject to numerous conditions, including final approval by Bentley’s Board of Directors and the effectiveness of the registration statement on Form 10, which is subject to review by the SEC. Bentley’s generic pharmaceuticals business manufactures and markets a growing portfolio of generic and branded generic products in Europe for the treatment of cardiovascular, gastrointestinal, infectious and central nervous system diseases through its subsidiaries -- Laboratorios Belmac, Laboratorios Davur, Laboratorios Rimafar and Bentley Pharmaceuticals Ireland. Bentley also manufactures and markets active pharmaceutical ingredients through its subsidiary, Bentley API. Additional information regarding Bentley Pharmaceuticals may be obtained through Bentley’s website at www.bentleypharm.com.